New cancer drug shows promise in early safety testing
NCT ID NCT04446260
Summary
This study tested the safety and early effectiveness of an experimental drug called SHR-A1811 in people with advanced solid tumors that have a specific marker called HER2. The trial involved 396 participants whose cancer had progressed despite standard treatments. Researchers monitored side effects and how the drug moved through the body while also checking for any early signs of tumor shrinkage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Hospital
Melbourne, 3004, Australia
-
Asan Medical Center
Seoul, 5505, South Korea
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Chang Gung Memorial Hospital, Linkou
Taoyuan District, 333, Taiwan
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Fudan University Shanghai cancer center
Shanghai, Shanghai Municipality, 200032, China
-
Fudan Unversity Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032, China
-
Fujian Cancer Hospital
Fujian, Fuzhou, 350000, China
-
Greenville Hospital System
Greenville, South Carolina, 29605, United States
-
Henan cancer Hospital
Zhengzhou, Henan, 450003, China
-
Hubei cancer hospital
Wuhan, Hubei, 430079, China
-
Hunan cancer hospital
Changsha, Hunan, 410031, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210000, China
-
Macquarie University Hospital
Macquarie, New South Wales, 2109, Australia
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Montefiore-Einstein Center for Cancer Care
The Bronx, New York, 10461, United States
-
Nanfang Hospital
Guangzhou, Guangdong, 510120, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
-
National Cheng Kung University Hospital
Tainan, 70457, Taiwan
-
Nucleus Network
Melbourne, Victoria, 3004, Australia
-
Peninsula and South Eastern Haematology & Oncology Group
Frankston, Victoria, 3199, Australia
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
Seoul, 3080, South Korea
-
Shanghai Jiao Tong University School of Medicine Renji Hospital
Shanghai, Shanghai Municipality, 200032, China
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, 030000, China
-
Shengjing Hospital of China medical university
Shengyang, Liaoning, 110022, China
-
Sichuan Cancer Hospital
Chengdu, Sichuan, 610042, China
-
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, 5042, Australia
-
Sun Yat-Sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
-
The first affiliated hospital of bengbu medical college
Bengbu, Anhui, 233000, China
-
The second affiliated hospital Zhejiang university school of medicine
Hangzhou, Zhejiang, 310014, China
-
Tianjin medical university cancer institute&hoospital
Tianjin, Tianjin Municipality, 300181, China
-
Xiangya hospital central south university
Changsha, Hunan, 410008, China
-
Zhejiang provincial people's hospital
Hangzhou, Zhejiang, 310014, China
-
Zhongnan hospital of Wuhan university
Wuhan, Hubei, 430062, China
Conditions
Explore the condition pages connected to this study.